SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO, Director, 10% Owner | 2026-06-30 | Open-market buy | 12500 | $250K |
| Mosseri Marlio Charles | 10% Owner | 2026-06-30 | Open-market buy | 50000 | $916K |
| Hoberman Kenneth | Director | 2026-06-11 | Grant/award | 35000 | $0 |
| Kaplan Matthew L. | Director | 2026-06-11 | Grant/award | 35000 | $0 |
| Oliviero James F III | Director | 2026-06-11 | Grant/award | 35000 | $0 |
| Sanchez Juan | Director | 2026-06-11 | Grant/award | 35000 | $0 |
| BENTSUR RON | Chairman & CEO, Director, 10% Owner | 2026-01-06 | Grant/award | 150000 | $0 |
| Carson Michael J. | Vice President, Finance | 2026-01-06 | Grant/award | 61200 | $0 |
| Poradosu Enrique | Chief Science & Business Off | 2026-01-06 | Grant/award | 150000 | $0 |
| Shemesh Shay | Chief Dev. & Ops. Officer | 2026-01-06 | Grant/award | 150000 | $0 |
| BENTSUR RON | Chairman & CEO, Director, 10% Owner | 2025-11-05 | Open-market buy | 5000 | $29K |
| Kaplan Matthew L. | Director | 2025-11-05 | Open-market buy | 11000 | $64K |
| Sanchez Juan | Director | 2025-11-05 | Open-market buy | 13000 | $75K |
| Mosseri Marlio Charles | 10% Owner | 2025-10-27 | Open-market buy | 72836 | $457K |
| Mosseri Marlio Charles | 10% Owner | 2025-10-24 | Open-market buy | 35034 | $215K |
| Mosseri Marlio Charles | 10% Owner | 2025-10-23 | Open-market buy | 46900 | $284K |
| Sanchez Juan | Director | 2025-09-22 | Grant/award | 30000 | $0 |
Nuvectis entered into an underwriting agreement on June 29, 2026 to conduct a registered public offering of 5,000,000 shares of common stock at $20.00 per share, generating $100 million in gross proceeds (or $115 million if underwriters exercise their 30-day option for 750,000 additional shares), resulting in net proceeds of approximately $93–107 million after underwriting fees.
View raw filing on EDGAR →The Company reduced the available sales capacity under its ATM (at-the-market) offering from an unspecified prior amount to $5 million and suspended the Sales Agreement Prospectus effective June 29, 2026. This represents a material reduction in the Company's access to capital markets and signals potential liquidity constraints or a shift in financing strategy. While not a traditional debt issuance or dilutive equity placement, this capital-raising modification is a financial event material to investor assessment of the registrant's liquidity position.
View raw filing on EDGAR →Nuvectis entered into a material definitive license agreement with Haisco Pharmaceutical Group on June 22, 2026, acquiring exclusive ex-China rights to develop, manufacture, and commercialize two clinical-stage drug candidates (NXP100 and NXP200). The transaction involves an upfront payment of $20 million, up to $20 million in initial development milestones, and up to $1.4 billion in contingent payments, representing a material acquisition of intellectual property and development rights that transforms the company's pipeline and strategy.
View raw filing on EDGAR →This Item 5.07 discloses the results of Nuvectis Pharma's 2026 Annual Meeting held on June 11, 2026, including voting outcomes for the election of a Class I director (Ron Bentsur) and ratification of Kesselman & Kesselman as independent auditor. All proposals were approved. While the filing notes a minor correction to the share count in the proxy statement (27.7M stated vs. 26.6M actual), this does not affect vote validity or outcomes. The core disclosure is the shareholder vote results, which is material to investors as it confirms board composition and auditor selection.
View raw filing on EDGAR →